DENTSPLY SIRONA Inc

XRAY is in a confirmed Stage 4 decline, with persistent lower highs and lower lows under declining EMAs and SMAs, indicating supply dominance. Medium-term directional asymmetry is bearish, favoring further downside. Short-term, deeply oversold RSI has produced a modest relief bounce with price pulling back into declining EMAs, offering no clear entry signal, so timing is neutral. A trim into rallies toward the 9 EMA, 20 EMA, and 50 SMA is advised, looking for rejection at resistance.

• ↑Q2 operating cash flow reached $99M versus $48M year-ago
• ↑Return to Growth Action Plan emphasizes clinical education and innovation
• ↓Q2 revenue $898M (-4.1% YoY); adjusted EPS flat at $0.52